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Supplementary Figure 1. Study design  
 
*Indicates groups where patients were required to have a confirmed BRCAm; †Seven patients were 
enrolled into group 5.1, six patients received treatment  
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Supplementary Table 1. Patient inclusion and exclusion criteria 
Patients had to fulfil the following criteria for inclusion into the study: The following were regarded as criteria for exclusion from the study: 
≥18 years of age and a life expectancy of ≥16 weeks Major surgery within 2 weeks of starting the study, and patients must have 
recovered from any effects of any major surgery 
Histologically confirmed malignant advanced solid tumour which was 
refractory to standard therapies (except group 8 patients who were not 
platinum refractory) or for which no suitable effective standard therapy 
existed. If a diagnosis based on a histological sample was not available, a 
diagnosis based on cytology was allowed for those tumour entities in which 
this method was a generally accepted alternative 
Patients who received any chemotherapy, radiotherapy (except for palliative 
reasons), or any other anticancer therapy within 4 weeks from the last dose 
prior to study randomization (or a longer period depending on the defined 
characteristics of the agents used). Patients were allowed to continue the use 
of bisphosphonates for bone metastases and corticosteroids, provided the 
dose was stable before and during the study and these were started at least 
4 weeks prior to the beginning of study treatment. Patients were allowed to 
continue on hormone replacement therapy and on luteinizing-hormone-
releasing hormone (LHRH) 
ECOG performance status 0–1 (group 8 only)  
ECOG performance status 0–2 (all other groups) 
Patients with symptomatic uncontrolled brain metastases 
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Patients had to fulfil the following criteria for inclusion into the study: The following were regarded as criteria for exclusion from the study: 
Patients must have had adequate organ and bone marrow function measured 
within 7 days prior to administration of study treatment as defined below:  
 Haemoglobin ≥10.0 g/dL and no blood transfusions in the 4 weeks prior 
to randomization (group 8 only); ≥9.0 g/dL (all other groups)  
 Absolute neutrophil count (ANC) ≥1.5x109/L  
 No dysplastic features on peripheral blood smear (group 8 only)  
 White blood cells (WBC) >3x109/L  
 Platelet count ≥100x109/L  
 Total bilirubin ≤1.5x institutional upper limit of normal (ULN) 
 Aspartate transaminase (AST [SGOT])/alanine transaminase (ALT 
[SGPT]) ≤2.5xULN unless liver metastases were present, in which case 
it must have been ≤5xULN  
 Serum creatinine ≤1.5xULN 
Patients considered a poor medical risk owing to a serious, uncontrolled 
medical disorder, non-malignant systemic disease or active, uncontrolled 
infection 
Patients unable to swallow orally administered medication and patients with 
gastrointestinal disorders likely to interfere with absorption of the study 
medication 
Pregnant or breastfeeding women 
Immunocompromised patients, eg, patients who were known to be 
serologically positive for human immunodeficiency virus (HIV) and were 
receiving antiviral therapy 
Patients with known hepatic disease 
Persistent toxicities (CTCAE grade 2 or greater) caused by previous cancer 
therapy (excluding alopecia) 
Female patients must have had evidence of non-childbearing status: negative 
urine or serum pregnancy test within 7 days of study treatment for women of 
childbearing potential, or postmenopausal status 
Treatment with any investigational product during the previous 14 days (or a 
longer period depending on the defined characteristics of the agents used) 
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Patients had to fulfil the following criteria for inclusion into the study: The following were regarded as criteria for exclusion from the study: 
Patients must have had solid tumours originating from the ovary or breast 
with a confirmed genetic BRCA1/2 mutation (group 8 gBRCA ovarian 
[including primary peritoneal and fallopian tube] cancer patients only). The 
mutation must have been confirmed as a loss-of-function mutation, ie, a 
known deleterious or suspected deleterious mutation (groups 1, 6, 7 and 8) 
Patients who were at the time of the study experiencing seizures or who were 
at the time of the study being treated with only anti-epileptics for seizures 
(use of anti-epileptic drugs to control pain was allowed in patients not 
suffering from seizures), unless drug was excluded because of CYP3A4 
induction 
Patients must have had at least one lesion, not previously irradiated, that 
could be accurately measured as ≥10 mm in the longest diameter with spiral 
computed tomography (CT) or as ≥20 mm with conventional techniques 
(conventional CT or magnetic resonance imaging [MRI]) and which was 
suitable for accurate repeated measurements (groups 1, 6, 7 and 8) 
Patients who received the following classes of inhibitors of CYP3A4  
(azole antifungals, macrolide antibiotics, protease inhibitors) 
Group 8 only: 
 Patients with myelodysplastic syndromes/acute myeloid leukemia 
 Patients who were platinum refractory 
 Patients who had previously received a PARP inhibitor 
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Pharmacodynamics 
Methods 
Samples for assessment of PARP inhibition in peripheral blood mononuclear cells 
(PBMC) were collected from patients participating in stage 1 of the study, in each of the 
single-dose treatment periods at pre-dose and 3, 10 and 24 hours post-dose. 
 
Supplementary Table 2. Mean percentage inhibition of PARP-1 from baseline  
(± standard error) in peripheral blood mononuclear cell (PBMC) samples following 
administration of single oral doses of the tablet or capsule formulation (n=6 per 
cohort; stage 1) 
Time after 
dose (h) 
Tablet formulation Capsule formulation 
 25 mg 
dose 
50 mg 
dose 
250 mg 
dose 
50 mg 
dose 
100 mg 
dose 
400 mg 
dose 
3 49.4 ± 43.5 58.2 ± 22.0 22.4 ± 43.0 42.8 ± 282 66.9 ± 167 50.5 ± 274 
10 69.9 ± 31.0 74.9 ± 55.0 89.4 ± 63.0 66.9 ± 331 55.7 ± 47.0 83.7 ± 28.0 
24 39.0 ± 45.0 41.5 ± 174 46.2 ± 215 16.7 ± 402 83.6 ± 100 54.4 ± 256 
Median PARP inhibition relative to baseline ranged over 22–67% 3 hours after dosing, with maximum 
levels 10 hours post-dose 
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Supplementary Table 3. Germline BRCA mutation status of patients in dose-
expansion groups 1, 6 and 8 
aOne patient was incorrectly stratified as having primary breast cancer, when this should have been 
stratified as ovarian cancer. This patient was excluded from the ovarian cancer subset as this was 
based on randomization stratification data but included as ovarian cancer in summaries of primary 
  BRCA mutation type 
Treatment group Primary 
tumour 
location 
BRCA1 BRCA2 BRCA1 and 
BRCA2 
 Group 1     
200 mg TAB (n=13) Ovary (n=8)a 5 2 1 
Breast (n=5) 1 1 3 
400 mg CAP (n=11) Ovary (n=7) 3 1 3 
Breast (n=4)b 0 3 0 
Group 6     
300 mg TAB (n=18) Ovary (n=13) 10 3 0 
Breast (n=5) 2 3 0 
400 mg TAB (n=17) Ovary (n=12) 9 3 0 
Breast (n=5) 3 2 0 
400 mg CAP (n=18) Ovary (n=13) 9 4 0 
Breast (n=5) 4 1 0 
Group 8     
200 mg TID TAB cont 
(n=16) 
Ovary (n=16) 11 3 2 
250 mg TID TAB inter 
(n=15) 
Ovary (n=15) 12 3 0 
400 mg BD TAB inter 
(n=16) 
Ovary (n=16) 13 3 0 
400 mg OD TAB cont 
(n=15) 
Ovary (n=15) 9 6 0 
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tumour location; bBRCAm data missing for one patient with breast cancer receiving 400 mg CAP. 
CAP, capsule formulation; cont, continuous dosing schedule; inter, intermittent dosing schedule; TAB, 
tablet formulation. 
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Supplementary Table 4. Pharmacokinetic parameters and relative bioavailability for olaparib following single dosing of CAP 
and TAB formulations in cohorts 1–3 and following multiple doses of CAP 200 mg and TAB 200 mg in the PK comparison phase 
of group 2  
 
Olaparib dose and formulation groups 
Cohort 1  Cohort 2  Cohort 3 
PK parameter 
25 mg  
TAB 
50 mg 
CAP  
50 mg  
TAB 
100 mg 
CAP  
250 mg  
TAB 
400 mg  
CAP 
Cmax (μg/mL), geometric mean (CV%) 1.17 (48) 1.82 (26)  2.22 (36) 2.90 (23)  8.81 (23) 5.67 (47) 
tmax (h), median  
(range) 
1.0 
(0.5–3.0) 
1.5 
(1.0–3.0) 
 0.5 
(0.5–2.0) 
1.25 
(1.0–2.0) 
 1.25 
(1.0–4.0) 
1.25 
(1.0–8.0) 
AUC (μg·h/mL), geometric mean (CV%) 5.15 (69) 10.0 (45)  8.34 (42) 16.9 (32)  63.0 (37) 57.9 (78) 
Half-life (h), arithmetic mean (SD) 7.27 (0.79) 7.87 (1.72)  7.47 (1.02) 8.44 (2.94)  6.17 (0.88) 11.9 (4.82) 
CL/F (L/h), arithmetic mean (SD) 5.65 (3.29) 5.38 (2.37)  6.42 (2.60) 6.18 (2.08)  4.19 (1.64) 8.64 (7.11) 
Varea/F (L), mean (SD) 59.3 (36.3) 60.6 (31.3)  69.2 (31.2) 81.1 (49.8)  36.2 (10.7) 167 (196) 
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Olaparib dose and formulation groups 
Cohort 1  Cohort 2  Cohort 3 
Relative bioavailability 25 mg TAB 
vs 50 mg CAP 
 50 mg TAB 
vs 100 mg CAP 
 250 mg TAB 
vs 400 mg CAP 
Cmax ratioa (90% CI) 1.29 (1.10–1.52)  1.53 (1.11–2.11)  2.49 (1.87–3.31) 
AUC ratioa (90% CI) 1.03 (0.85–1.24)  0.99 (0.69–1.42)  1.74 (1.36–2.23) 
 PK comparison phase of group 2, 200 mg TAB and 400 mg CAP – crossover 
PK parameter 200 mg TAB  400 mg CAP  TAB:CAP ratio 
Cmax,ss (μg/mL), geometric mean (CV%) 8.02 (38)  8.10 (35)  0.991 
AUCss (μg·h/mL), geometric mean (CV%) 38.36 (46)  48.48 (52)  0.791 
Cmin,ss (μg/mL), geometric mean (CV%) 0.68 (86)  1.38 (101)  0.540 
aCmax and AUC values were normalized for administered dose. CV, coefficient of variation 
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Supplementary Table 5. Number (%) of patients who had at least one AE of any grade (≥20% incidence in any treatment group) 
in the dose-expansion phase for groups 1 (200 mg TAB and 400 mg CAP) and 6 and dose-escalation groups 3, 4, 5, 5.1 and 5.2 
 Group 1 Group 3 Group 4 Group 5 Group 5.1 Group 5.2 
Group 6 
 200 mg BD 
TAB 
400 mg BD 
CAP 
250 mg BD 
TAB 
300 mg BD 
TAB 
350 mg BD 
TAB 
400 mg BD 
TAB 
450 mg BD 
TAB 
300 mg BD 
TAB 
400 mg BD 
TAB 
400 mg BD  
CAP 
 n=13 n=11 n=6 n=6 n=6 n=6 n=6 n=18 n=17 n=18 
Any AE, n (%) 13 (100) 10 (91) 6 (100) 6 (100) 6 (100) 6 (100) 6 (100) 18 (100) 17 (100) 18 (100) 
Blood and lymphatic system disorders 
Anaemia 1 (8) 0 1 (17) 2 (33) 1 (17) 2 (33) 3 (50) 7 (39) 9 (53) 6 (33) 
Neutropenia 0 0 0 1 (17) 0 1 (17) 1 (17) 3  (17) 1 (6) 2 (11) 
Thrombocytopenia 0 0 0 0 0 0 1 (17) 1 (6) 3 (18) 0 
Gastrointestinal disorders 
Abdominal pain 1 (8) 1 (9) 0 1 (17) 2 (33) 1 (17) 1 (17) 2 (11) 2 (12) 0 
Constipation 7 (54) 1 (9) 3 (50) 1 (17) 1 (17) 3 (50) 2 (33) 4 (22) 1 (6) 2 (11) 
Diarrhoea 4 (31) 3 (27) 4 (67) 4 (67) 2 (33) 1 (17) 3 (50) 9 (50) 4 (24) 2 (11) 
Dyspepsia 1 (8) 2 (18) 3 (50) 2 (33) 0 0 3 (50) 1 (6) 2 (12) 3 (17) 
Nausea 10 (77) 7 (64) 5 (83) 5 (83) 5 (83) 6 (100) 5 (83) 13 (72) 15 (88) 15 (83) 
Stomatitis 0 0 0 0 2 (33) 1 (17) 2 (33) 0 1 (6) 1 (6) 
Vomiting 5 (39) 3 (27) 2 (33) 4 (67) 1 (17) 1 (17) 0 8 (44) 6 (35) 5 (28) 
General disorders 
Alopecia 0 1 (9) 0 0 1 (17) 0 2 (33) 1 (6) 1 (6) 1 (6) 
Oedema 
peripheral 
1 (8) 1 (9) 1 (17) 0 2 (33) 1 (17) 2 (33) 4 (22) 1 (6) 1 (6) 
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 Group 1 Group 3 Group 4 Group 5 Group 5.1 Group 5.2 
Group 6 
 200 mg BD 
TAB 
400 mg BD 
CAP 
250 mg BD 
TAB 
300 mg BD 
TAB 
350 mg BD 
TAB 
400 mg BD 
TAB 
450 mg BD 
TAB 
300 mg BD 
TAB 
400 mg BD 
TAB 
400 mg BD  
CAP 
 n=13 n=11 n=6 n=6 n=6 n=6 n=6 n=18 n=17 n=18 
Fatigue 9 (69) 5 (45) 5 (83) 6 (100) 3 (50) 5 (83) 4 (67) 13 (72) 14 (82) 9 (50) 
Non-cardiac chest 
pain 
1 (8) 0 0 2 (33) 0 0 0 1 (6) 2 (12) 0 
Pyrexia 0 0 0 1 (17) 0 0 0 0 6 (35) 0 
Infections 
Lower respiratory 
tract infection 
0 1 (9) 1 (17) 2 (33) 0 1 (17) 1 (17) 2 (11) 3 (18) 2 (11) 
Urinary tract 
infection 
2 (15) 1 (9) 1 (17) 0 0 1 (17) 0 7 (39) 3 (18) 2 (11) 
Metabolism and nutritional disorders 
Decreased 
appetite 
7 (54) 3 (27) 2 (33) 2 (33) 1 (17) 3 (50) 1 (17) 9 (50) 5 (29) 8 (44) 
Musculoskeletal disorders 
Arthralgia 2 (15) 2 (18) 0 3 (50) 0 1 (17) 1 (17) 2 (11) 1 (6) 2 (11) 
Back pain 5 (39) 3 (27) 1 (17) 1 (17) 0 0 1 (17) 3 (17) 4 (24) 2 (11) 
Musculoskeletal 
chest pain 
3 (23) 0 0 0 1 (17) 0 1 (17) 0 1 (6) 1 (6) 
Musculoskeletal 
pain 
0 1 (9) 0 1 (17) 0 0 2 (33) 2 (11) 3 (18) 0 
Pain in extremity 2 (15) 1 (9) 0 1 (17) 0 2 (33) 0 0 1 (6) 1 (6) 
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 Group 1 Group 3 Group 4 Group 5 Group 5.1 Group 5.2 
Group 6 
 200 mg BD 
TAB 
400 mg BD 
CAP 
250 mg BD 
TAB 
300 mg BD 
TAB 
350 mg BD 
TAB 
400 mg BD 
TAB 
450 mg BD 
TAB 
300 mg BD 
TAB 
400 mg BD 
TAB 
400 mg BD  
CAP 
 n=13 n=11 n=6 n=6 n=6 n=6 n=6 n=18 n=17 n=18 
Nervous system disorders 
Dizziness 1 (8) 1 (9) 0 1 (17) 0 2 (33) 0 2 (11) 1 (6) 0 
Dysgeusia 0 0 1 (17) 2 (33) 0 0 1 (17) 6 (33) 3 (18) 2 (11) 
Headache 1 (8) 0 1 (17) 1 (17) 1 (17) 2 (33) 3 (50) 2 (11) 1 (6) 2 (11) 
Paraesthesia 1 (8) 1 (9) 0 0 1 (17) 0 2 (33) 0 0 1 (6) 
Renal and urinary disorders 
Pollakiuria 0 0 0 2 (33) 0 0 0 1(6) 0 0 
Respiratory, thoracic and mediastinal disorders 
Cough 5 (39) 1 (9) 2 (33) 1 (17) 1 (17) 1 (17) 0 3 (17) 2 (12) 2 (11) 
Dyspnoea 2 (15) 2 (18) 0 1 (17) 0 1 (17) 1 (17) 5 (28) 4 (24) 4 (22) 
Dyspnoea 
exertional 
1 (8) 0 0 0 0 1 (17) 2 (33) 2 (11) 1 (6) 1 (6) 
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Supplementary Table 6. Summary of haematological toxicity ‒ maximum overall CTCAE grade change in haemoglobin (g/L), 
neutrophils (109/L) and platelets (109/L) during treatment for groups 6 and 8  
Group/treatment 
Baseline CTCAE 
gradea 
Total 
Patients at baseline with one 
on-treatment measurement, n (%)b 
Patients with maximum overall CTCAE grade  
during treatment, n (%)c 
Grade ≤2 Grade 3 Grade 4 
Group 6      
300 mg BD TAB Haemoglobin 
0 
1 
2 
Total 
 
6 (33.3) 
10 (55.6) 
2 (11.1) 
18 (100) 
 
5 (27.7) 
8 (44.4) 
1 (5.6) 
14 (77.7) 
 
1 (5.6) 
1 (5.6) 
0 
2 (11.1) 
 
0 
1 (5.6) 
1 (5.6) 
2 (11.1) 
400 mg BD TAB Haemoglobin 
0 
1 
2 
Total 
 
8 (47.1) 
6 (35.3) 
3 (17.6) 
17 (100) 
 
4 (23.5) 
5 (29.4) 
2 (11.8) 
11 (64.7) 
 
2 (11.8) 
1 (5.9) 
1 (5.9) 
4 (23.5) 
 
2 (11.8) 
0 
0 
2 (11.8) 
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Group/treatment 
Baseline CTCAE 
gradea 
Total 
Patients at baseline with one 
on-treatment measurement, n (%)b 
Patients with maximum overall CTCAE grade  
during treatment, n (%)c 
Grade ≤2 Grade 3 Grade 4 
400 mg BD CAP Haemoglobin 
0 
1 
Total 
 
12 (66.7) 
6 (33.3) 
18 (100) 
 
11 (61.1) 
5 (27.7) 
16 (88.8) 
 
1 (5.6) 
1 (5.6) 
2 (11.1) 
 
0 
0 
0 
Group 8      
200 mg TID TAB 
cont 
Haemoglobin 
0 
1 
Total 
 
11 (68.8) 
5 (31.3) 
16 (100) 
 
10 (62.5) 
5 (31.3) 
15 (93.8) 
 
1 (6.3) 
0 
1 (6.3) 
 
0 
0 
0 
250 mg TID TAB 
inter 
Haemoglobin 
0 
1 
Total 
 
11 (73.3) 
4 (26.7) 
15 (100) 
 
11 (73.3) 
3 (20.0) 
14 (93.3) 
 
0 
1 (6.7) 
1 (6.7) 
 
0 
0 
0 
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Group/treatment 
Baseline CTCAE 
gradea 
Total 
Patients at baseline with one 
on-treatment measurement, n (%)b 
Patients with maximum overall CTCAE grade  
during treatment, n (%)c 
Grade ≤2 Grade 3 Grade 4 
400 mg BD TAB 
inter 
Haemoglobin 
0 
1 
Total 
 
13 (81.3) 
3 (18.8) 
16 (100) 
 
13 (81.3) 
3 (18.8) 
16 (100) 
 
0 
0 
0 
 
0 
0 
0 
400 mg TID TAB 
cont 
Haemoglobin 
0 
1 
Total 
 
10 (66.7) 
5 (33.3) 
15 (100) 
 
10 (66.7) 
5 (33.3) 
15 (100) 
 
0 
0 
0 
 
0 
0 
0 
aBaseline was defined as the last result obtained prior to the start of olaparib; bPatients with a baseline value and at least one on-treatment value; 
percentages have been calculated using the number of patients at baseline; cDerived from laboratory assessments between the start of treatment and 
30 days following the date of last dose of olaparib 
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Supplementary Table 7. Summary of number (%) of patients with interruptions and dose reductions of olaparib as a result of 
adverse events for groups 6 and 8 
  Number of patients with an interruption Number of patients with a dose reduction Total number of patients with a dose 
interruption and/or reduction 
 n Total 1 2 ≥3 AE Total 1 2 ≥3 AE Total 1 2 ≥3 AE 
Group 6                 
300 mg BD TAB 18 8 
(44.4) 
3 
(16.7) 
2 
(11.1) 
3 
(16.7) 
7 
(38.9) 
4 
(22.2) 
3 
(16.7) 
0 1  
(5.6) 
4 
(22.2) 
9 
(50.0) 
2 
(11.1) 
3 
(16.7) 
4 
(22.2) 
8 
(44.4) 
400 mg BD TAB 17 10 
(58.8) 
5 
(29.4) 
4 
(23.5) 
1 
(5.9) 
10 
(58.8) 
11 
(64.7) 
7 
(41.2) 
2 
(11.8) 
2 
(11.8) 
11 
(64.7) 
13 
(76.5) 
4 
(23.5) 
2 
(11.8) 
7 
(41.2) 
13 
(76.5) 
400 mg BD CAP 18 6 
(33.3) 
3 
(16.7) 
2 
(11.1) 
1 
(5.6) 
3 
(16.7) 
3 
(16.7) 
3 
(16.7) 
0 0 3 
(16.7) 
8 
(44.4) 
4 
(22.2) 
3 
(16.7) 
1  
(5.6) 
6 
(33.3) 
Group 8                 
200 mg  TID TAB 
cont 
16 13 
(81.3) 
2 
(12.5) 
4 
(25.0) 
7 
(43.8) 
7 
(43.8) 
4 
(25.0) 
3 
(18.8) 
1  
(6.3) 
0 3 
(18.8) 
13 
(81.3) 
2 
(12.5) 
2 
(12.5) 
9 
(56.3) 
7 
(43.8) 
250 mg TID TAB 
inter 
15 11 
(73.3) 
1  
(6.7) 
2 
(13.3) 
8 
(53.3) 
7 
(46.7) 
2 
(13.3) 
2 
(13.3) 
0 0 1  
(6.7) 
11 
(73.3) 
1  
(6.7) 
2 
(13.3) 
8 
(53.3) 
7 
(46.7) 
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  Number of patients with an interruption Number of patients with a dose reduction Total number of patients with a dose 
interruption and/or reduction 
 n Total 1 2 ≥3 AE Total 1 2 ≥3 AE Total 1 2 ≥3 AE 
400 mg BD TAB 
inter 
16 16 
(100) 
6 
(37.5) 
3 
(18.8) 
7 
(44.0) 
8 
(50.0) 
6 
(37.5) 
5 
(31.3) 
0 1  
(6.3) 
6 
(37.5) 
16 
(100) 
4 
(25.0) 
5 
(31.3) 
7 
(43.8) 
8 
(50.0) 
400 mg OD TAB 
cont 
15 7 
(46.7) 
3 
(20.0) 
2 
(13.3) 
2 
(13.3) 
5 
(33.3) 
2 
(13.3) 
1  
(6.7) 
0 1  
(6.7) 
2 
(13.3) 
7 
(46.7) 
3 
(20.0) 
2 
(13.3) 
2 
(13.3) 
5 
(33.3) 
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Supplementary Figure 2. Waterfall plots of percentage change in target lesion size 
at 16 weeks (a) following multiple dosing of olaparib capsule 400 mg BD (groups 1 
and 6), (b) following multiple dosing of the tablet 200 mg BD to patients in group 1, 
(c) following multiple dosing of the tablet 300 mg BD to patients in group 6,  
(d) following multiple dosing of the tablet 400 mg BD to patients in group 6,  
(e) following continuous dosing of the tablet 200 mg TID to patients in group 8,  
(f) following intermittent dosing of the tablet 250 mg TID to patients in group 8,  
(g) following intermittent dosing of the tablet 400 mg TID to patients in group 8, 
and (h) following continuous dosing of the tablet 400 mg OD to patients in group 8  
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